论文部分内容阅读
腹膜炎是长期腹膜透析(下称腹透)的重要并发症,革兰氏阳性菌占腹膜炎总数的2/3。常规应用肠道外或腹腔内抗生素治疗,以往头孢霉素、妥布霉素或庆大霉素为治疗腹膜炎的第一线药物。今天,万古霉素系对革兰氏阳性有效的广谱抗生素被视为第二线药物。本文报道静脉注射万古素霉治疗腹膜炎的良好效果。作者对112例长期腹透患者进行观察,腹膜炎诊断包括腹透液混浊和/或腹痛,腹透液中白细胞计数>100/mm~3,腹透液培养和药敏试验。结果革兰氏阳性菌99次占68.7%,革兰氏阴性菌23.1%,培养阴性8.2%。42例腹膜炎患者有62次为革兰氏阳性菌,其中金黄色葡萄球菌共35例次(57.4%),表皮葡萄球菌15例次(24.8%),D型链球菌5例次(8.2%),
Peritonitis is an important complication of long-term peritoneal dialysis (hereinafter referred to as peritoneal dialysis), Gram-positive bacteria account for 2/3 of the total number of peritonitis. Conventional application of parenteral or intraperitoneal antibiotics, cephalosporins, tobramycin or gentamicin in the past for the treatment of peritonitis first-line drugs. Today, vancomycin is a second-line drug for Gram-positive broad-spectrum antibiotics. This article reports the good effect of intravenous injection of V. vancomycin in the treatment of peritonitis. The authors observed 112 cases of patients with long-term peritoneal dialysis. Peritonitis was diagnosed by peritoneal opacification and / or abdominal pain, leukocyte counts in peritoneal fluid> 100 / mm3, dialysate culture and susceptibility testing. Results Gram-positive bacteria accounted for 68.7% 99 times, Gram-negative bacteria 23.1%, culture negative 8.2%. Of the 42 patients with peritonitis, 62 were Gram-positive bacteria, including 35 cases (57.4%) of Staphylococcus aureus, 15 cases (24.8%) of Staphylococcus epidermidis and 5 cases (8.2%) of Group D streptococcus ,